Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0OLQNU
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
TRSQ-ZP3A-LP20
|
|||||
| Synonyms |
TRSQ-ZP3A-LP20
Click to Show/Hide
|
|||||
| Organization |
REGENERON PHARMACEUTICALS, INC.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.95
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-STEAP2 mAb
|
Antibody Info | ||||
| Antigen Name |
Metalloreductase STEAP2 (STEAP2)
|
Antigen Info | ||||
| Payload Name |
CL202203715A1 P11
|
Payload Info | ||||
| Linker Name |
DIBAC-PEG4-vcPAB
|
Linker Info | ||||
| Conjugate Type |
DBCO-Azide Click Chemistry Conjugation
|
|||||
| Combination Type |
LP20
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 1.366 nM | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 25% FBS,penicillin/streptomycin and L-glutamine.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||